Navigation Links
JHP Pharmaceuticals Enters Another Multi-Year Contract Manufacturing Agreement

PARSIPPANY, N.J., Feb. 24, 2011 /PRNewswire/ -- JHP Pharmaceuticals, a leading provider of contract manufacturing services for sterile injectable products, announced today that it has entered into a multi-year contract manufacturing agreement with an undisclosed biotechnology company. JHP will be responsible for manufacturing and supply of an approved therapy used in cancer patients.

Stuart Hinchen, president and co-founder of JHP, stated, "We recognize that being selected to produce this crucial drug demonstrates our ability to meet critical marketplace needs. JHP was able to achieve the rigorous timelines required to manufacture this drug through a quality-driven, experienced staff and a customer-centric approach. Additionally, our record of cGMP compliance, coupled with our experience in manufacturing site transfers put us in the position to serve this important customer."

Hinchen also noted, "This will be the second multi-year contract JHP has entered during the last two months. These agreements are examples of how our approach to ongoing investment in our people and facilities allow us to focus on customer needs which results in rising, sustainable growth. Our Rochester, Michigan manufacturing site has a solid history of successful partnerships, manufacturing both clinical and commercial products."

About JHP Pharmaceuticals, LLC

JHP Pharmaceuticals, headquartered in New Jersey, provides contract manufacturing of sterile injectables, biologics, vaccines, ophthalmics and otics for large and small pharmaceutical and biotech organizations.

JHP's sterile manufacturing facility, located in Rochester Michigan sits on over 80 acres of land and includes a 171,000 sq. ft. production building and warehouse. The production facility utilizes three high-speed filling lines, four lyophilizers and a clinical fill line. The site also includes separate facilities for chemistry, sterility testing, and analytical methods development.

JHP has the capability to manufacture small-scale clinical through large-scale commercial products. JHP employs more than 330 staff in the USA in its manufacturing, product development, sales & marketing and corporate areas. For more information, please visit

SOURCE JHP Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
2. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
3. Jazz Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference in New York on March 1
4. Tarix Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell Transplant
5. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
6. Onyx Pharmaceuticals Reports Full Year and Fourth Quarter 2010 Financial Results
7. Avanir Pharmaceuticals to Present at Three Conferences in March
8. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
9. Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activity in a Phase 1 Study
10. Isis Pharmaceuticals to Present at the 2011 Citi Global Healthcare Conference
11. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
Post Your Comments:
(Date:10/12/2015)... HOUSTON , October 13, 2015 ... will be operating in a non-clinical capacity. --> ... will be operating in a non-clinical capacity. --> The ... recently completed installation of the first high field (1.5 Tesla) MRI-guided ... early next year, the system will be operating in a non-clinical ...
(Date:10/12/2015)... , Oct. 12, 2015 ... the setbacks and the needs of the medical membrane ... of membrane devices within the different medical membrane devices ... blood microfilters/apheresis systems and membrane diagnostic devices. - Gain ... in this market. --> Use this report ...
(Date:10/12/2015)... SAN DIEGO and CRANBURY, N.J. ... firm Robbins Arroyo LLP announces that a ... U.S. District Court for the District of New Jersey.  ... Therapeutics, Inc. (NASDAQGM: FOLD) violated the Securities Exchange Act ... 2015, by making materially false and misleading statements about ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... , ... Tempe Dental Care, a leading Tempe dentists’ office, celebrates offering gentle, ... for more than 5 years. A leading cause of emergency room visits, school ... is not timely. , Sedation dentistry provides an anxiety-free dental experience ...
(Date:10/13/2015)... ... ... Local Gold’s Gym franchise owner, Bryce Berry, received the Visionary of the ... and operates Gold's Gym Cheyenne in Cheyenne, Wyoming, received the award in ... A brand leader in global fitness, Gold’s Gyms are located worldwide. Every fitness center ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... Dr. Bill Saye as the newest professional to introduce the latest development, ThermiVa® ... highly recognized as a leading professional in Obstetrics and Gynecology and a pioneer ...
(Date:10/13/2015)... ... 2015 , ... In an ongoing effort to provide the ... Texas, child development and pediatric therapy center, is working with TRICARE to emphasize ... options for receiving this kind of care for affected children. Because of concerns ...
(Date:10/13/2015)... ... October 13, 2015 , ... Just under three months ago, ... began a $1 promotion – effectively offering all of their services for just a ... the company was flooded with phone calls from interested buyers. As a genuine one-stop-shop ...
Breaking Medicine News(10 mins):